A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/ Cedazuridine and Oral Decitabine/ Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). The purpose of this study is to test the safety and efficacy of tolinapant and INQOVI (decitabine and cedazuridine). This is a 3-part study:
• Part 1 (Lead-in) will determine the starting dose of oral decitabine/ cedazuridine tablet
• Part 2 (Phase 1) will help determine the doses and safety of the study drugs in combination

A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

The University of Virginia is conducting a clinical research study for adults ages 18 and over who have locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutation.

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have early stage triple-negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene and who have cancer remaining after neoadjuvant treatment and surgery. This study will test an experimental drug named sacituzumab govitecan in combination with pembrolizumab compared to pembrolizumab with or without capecitabine.

A phase 2 open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel concomitant with prophylactic steroids in subjects with relapsed or refractory large b-cell lymphoma in the outpatient setting

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with relapsed or refractory large b-cell lymphoma (LBLC) for a research study. The study product, KTE-C19, has demonstrated to be safe and effective when combined with prophylactic steroids in treating relapsed or refractory LBLC. The purpose of this study is to find out if the product, KTE-C19, is equally safe and effective when in the outpatient setting.

A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status

The University of Virginia is participating a clinical research study for adults ages 18 and over, who have either platinum-resistant ovarian carcinoma or endometrial adenocarcinoma. If you participate in this study you will either receive the study drug ACR-368 alone (arm 1) or in combination with Gemcitabine (Arm 2). ACR-368, an adenosine triphosphate–competitive selective inhibitor of checkpoint kinase (CHK)1 and CHK2 is an experimental drug.

A Phase 2 trial to evaluate the safety and efficacy of NKT2152 in Combination with Palbociclib (Doublet) and with Palbociclib and Sasanlimab (Triplet) in subjects with advanced or Metastatic Clear Cell Renal Cell Carcinoma.

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with advanced or Metastatic Clear Cell Renal Cell Carcinoma to participate in a research study. This study will evaluate whether an investigational drug not yet approved by the FDA, called NKT2152, will help in the treatment of renal cell carcinoma when combined with one or two other drugs, palbociclib and sasanlimab. The study will also evaluate how safe NKT2152 is to use in people when combined with these other investigational drugs, palbociclib and sasanlimab.

Study Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients

The University of Virginia Comprehensive Cancer Center is conducting a clinical research study for patients who are adults who are not able to improve their platelet count, despite platelet transfusions. There is currently no approved treatment for this condition. The purpose of this study is to learn whether infusions of a drug called isatuximab in this population may help platelet transfusions be more effective. Isatuximab is approved for the treatment of multiple myeloma (MM), a type of cancer, but not for this issue with platelets, so this use of the drug is investigational.

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Metastatic Solid Tumors Which Have Progressed Despite Standard Treatments

The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with metastatic solid tumors which have not responded to standard anti-cancer treatments to participate in a research study. This study will evaluate the investigational drug XL092 alone or in combination with nivolumab, nivolumab plus ipilimumab, or nivolumab/relatlimab fixed dose combination. This is an open label study, which means you, the study doctor, and the Sponsor will know which study treatment you were given.

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma

The University of Virginia is participating a clinical research study for adults ages 18 and over, who have cervical cancer that has come back after treatment (recurrent), has spread to other organs (metastatic) or has not improved (persistent) after the previous treatment. The purpose of this study is to find out:

Subscribe to